Hemispherx BioPharma (HEB) Stock Price, News & Analysis

Company Overview

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma and malignant melanoma. The company was founded in 1990 and is headquartered in Orlando, Florida.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.09 to $0.22
• 52-Week Range: N/A
• Volume: 2.31 million shs
• Average Volume: 102,599 shs
• Market Capitalization: $232,000.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

HEB Stock Analysis - Frequently Asked Questions

How were Hemispherx BioPharma's earnings last quarter?

Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) released its quarterly earnings data on Thursday, August, 15th. The specialty pharmaceutical company reported ($1.07) earnings per share for the quarter, topping the consensus estimate of ($1.70) by $0.63. The specialty pharmaceutical company had revenue of $0.03 million for the quarter.

When did Hemispherx BioPharma's stock split?

Hemispherx BioPharma's stock reverse split on the morning of Tuesday, June 11th 2019. The 1-44 reverse split was announced on Friday, May 31st 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 10th 2019. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of Hemispherx BioPharma?

Shares of HEB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Hemispherx BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Hemispherx BioPharma investors own include NewLink Genetics (NLNK), Goodrich Petroleum (GDPMQ), Biocept (BIOC), CTI BioPharma (CTIC), Inovio Pharmaceuticals (INO), Palatin Technologies (PTN) and Ayala Pharmaceuticals (ADXS).

Company Calendar

• Last Earnings: 8/15/2019
• Today: 4/20/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NYSEAMERICAN:HEB
• Previous Symbol: NYSE:HEB
• CIK: 946644
• Web: www.hemispherx.net
• Phone: +1-407-2718516
• Fax: N/A
• Employees: 31
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 2,442,000
• Free Float: N/A
• Market Cap: $232,000.00
• Optionable: Not Optionable
• Beta: N/A